On April 10, 2026, Celltrion, a global pharmaceutical powerhouse, made headlines with a significant disclosure: its stake in Celltrion Pharm, a fellow KOSDAQ-listed manufacturer, had quietly grown. According to a public filing, Celltrion now holds 24,416,241 shares in Celltrion Pharm, representing a 54.99% ownership as of the reporting date. This marks an increase from the previous year, when Celltrion's stake stood at 23,937,492 shares, or 54.81% as of April 10, 2025. The uptick—478,749 additional shares—resulted from a stock dividend issued on March 24, 2026, a move that underscores Celltrion’s continued commitment to consolidating its position in the pharmaceutical sector.
Celltrion Pharm, which has been trading on the KOSDAQ since February 3, 2006, saw its stock price close at 56,000 KRW at 16:10 KST on April 10, up 300 KRW from the previous day. The modest climb may seem unremarkable at first glance, but it comes amid a swirl of analyst optimism and shifting market dynamics for both Celltrion and its subsidiaries.
On that same day, Eugene Investment & Securities reaffirmed its bullish stance on Celltrion, maintaining a 'Buy' rating and a target price of 280,000 KRW. Analyst Kwon Hae-soon, who authored the report, noted that Celltrion’s stock price had risen about 11% since the start of the year. However, in a twist that might surprise some investors, the company’s share price underperformed the KOSPI by roughly 26 percentage points over the same period. "Considering external variables and quarterly performance volatility, we expect growth momentum to become more prominent in the second half of the year," Kwon wrote, adding, "The current stock price is at its lowest point for the year."
So, what’s fueling this cautious optimism? For one, Celltrion has managed to break out of a three-year period of sluggish growth, thanks to a series of new product launches. Eugene Investment & Securities expects this growth cycle to continue not only through 2026 but into 2027 as well, predicting that the company’s premium valuation will remain justified. "Given the product launch cycle, the growth trend is expected to continue in 2027," Kwon explained. "Accordingly, the valuation premium is justified, and as we move into the second half of the year, the momentum for earnings growth is expected to strengthen, leading to a rise in share price."
The brokerage’s target price of 280,000 KRW is based on a price-to-earnings ratio of 45 times the expected net income for 2026—a figure that reflects the firm’s confidence in Celltrion’s ability to sustain its premium status in the bio-pharmaceutical sector. The report also highlights robust financial expectations: Celltrion’s 2026 revenues are forecasted to grow by 25% year-over-year, while operating profit is projected to jump 36%—no small feat in a competitive global market.
But it’s not all smooth sailing. The report notes that legacy products are facing inevitable stagnation due to price cuts and intensifying competition. Yet, this challenge is being counterbalanced by the expansion of high-margin new products and a significant boost from contract manufacturing organization (CMO) sales, which are expected to reach around 300 billion KRW. "Existing products are bound to stagnate due to price cuts and increased competition, but overall, strong growth in both scale and profit is expected thanks to the expansion of high-margin new product sales and CMO revenue," Kwon stated.
There’s also a short-term wrinkle: the initial costs associated with bringing an Eli Lilly-acquired factory online are expected to temporarily raise cost ratios in the first half of 2026. This could mean that profitability for the year will hit its lowest point in the first half. However, the outlook brightens as the year progresses. "In the first half, the cost ratio is expected to rise temporarily due to the initial costs of operating the plant acquired from Eli Lilly, so annual profits are likely to bottom out in the first half," Kwon observed. "But as we move into the second half, improved factory utilization and a better product mix will expand the scope of performance improvement."
The Celltrion group’s recent moves—particularly the increase in its stake in Celltrion Pharm—appear to dovetail with this broader strategy of leveraging new products and operational efficiencies to drive growth. Celltrion Pharm, with its long-standing presence on the KOSDAQ and reputation as a reliable pharmaceutical manufacturer, remains a key part of this vision. The company’s steady performance, as reflected in its recent share price uptick, adds another layer of stability to the group’s overall outlook.
For investors, the story of Celltrion and Celltrion Pharm is a study in contrasts and calculated risk. On one hand, the group is navigating the headwinds of industry-wide price pressures and competition. On the other, it’s betting big on innovation, operational expansion, and strategic consolidation. The recent stock dividend, which increased Celltrion’s stake in Celltrion Pharm, is emblematic of this approach: rather than resting on its laurels, the company is actively reinforcing its foundation for future growth.
It’s also worth noting that the premium valuation assigned to Celltrion—45 times expected net income—signals a strong belief in the company’s growth prospects, especially as it shifts toward higher-margin products and ramps up CMO activities. This is not a sector where such confidence is handed out lightly; it’s earned through consistent performance, strategic foresight, and a willingness to adapt to changing market conditions.
As the second half of 2026 approaches, all eyes will be on Celltrion’s ability to translate its ambitious plans into tangible results. Will the anticipated growth in new product sales and improved factory utilization materialize as forecasted? Will the group’s calculated risks pay off, justifying its premium valuation and delivering the returns investors are hoping for?
For now, analysts like Kwon Hae-soon are betting that Celltrion’s best days this year are still ahead. The company’s recent moves—both in the boardroom and on the trading floor—suggest that it’s more than ready to meet the challenge.